We thank Sanquin for the financial support of this study and Geert W. Haasnoot and Leo M.G. van de Watering for their assistance in the statistical analyses.
References
1. Kissmeyer-Nielsen F, Olsen S, Petersen VP, Fjeldborg O. Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells. Lancet 1966;2: 662-665.
2. Opelz G, Sengar DP, Mickey MR, Terasaki PI. Effect of blood transfusions on subsequent kidney transplants. Transplant Proc 1973;5: 253-259.
3. Persijn GG, Cohen B, Lansbergen Q, van Rood JJ. Retrospective and prospective studies on the effect of blood transfusions in renal transplantation in The Netherlands. Transplantation 1979;28: 396-401.
4. Lagaaij EL, Hennemann IP, Ruigrok M et al. Effect of one-HLA-DR-antigen-matched and completely HLA-DR-mismatched blood transfusions on survival of heart and kidney allografts. N Engl J Med 1989;321: 701-705.
5. Kerman RH, Van Buren CT, Lewis RM, Kahan BD. Successful transplantation of 100 untransfused cyclosporine-treated primary recipients of cadaveric renal allografts. Transplantation 1988;45: 37-40.
6. van der Mast BJ, Balk AH. Effect of HLA-DR-shared blood transfusion on the clinical outcome of heart transplantation. Transplantation 1997;63: 1514-1519.
7. Bayle F, Masson D, Zaoui P, Janbon B, Bensa JC, Vialtel P. One HLA haplo-identical transfusion in first renal allograft recipients: effect on alloimmunisation, acute rejection episodes, and graft survival. Transplant Proc 1995;27: 2457-2458.
8. Bayle F, Masson D, Zaoui P et al. Beneficial effect of one HLA haplo- or semi-identical transfusion versus three untyped blood units on alloimmunization and acute rejection episodes in first renal allograft recipients. Transplantation 1995;59: 719-723.
9. Middleton D, Martin J, Douglas J, McClelland M. Transfusion of one HLA-DR antigen- matched blood to potential recipients of a renal allograft. Transplantation 1994;58: 845- 848.
10. Opelz G, Vanrenterghem Y, Kirste G et al. Prospective evaluation of pretransplant blood transfusions in cadaver kidney recipients. Transplantation 1997;63: 964-967.
11. Hiesse C, Busson M, Buisson C et al. Multicenter trial of one HLA-DR-matched or mismatched blood transfusion prior to cadaveric renal transplantation. Kidney Int 2001;60: 341-349.
12. Burke GW, III, Kaufman DB, Millis JM et al. Prospective, randomized trial of the effect of antibody induction in simultaneous pancreas and kidney transplantation: three-year results. Transplantation 2004;77: 1269-1275.
13. bou-Jaoude MM, Ghantous I, Almawi WY. Comparison of daclizumab, an interleukin 2 receptor antibody, to anti-thymocyte globulin-Fresenius induction therapy in kidney transplantation. Mol Immunol 2003;39: 1083-1088.
14. bou-Jaoude MM, Ghantous I, Najm R, Afif C, Almawi WY. Daclizumab versus anti- thymocyte globulin-fresenius as induction therapy for low-risk kidney transplant recipients. Transplant Proc 2003;35: 2731-2732.
15. Martins L, Fonseca I, Almeida M et al. Immunosuppression with antithymocyte globulin in renal transplantation: better long-term graft survival. Transplant Proc 2005;37: 2755- 2758.
16. Bock HA. Steroid-resistant kidney transplant rejection: diagnosis and treatment. J Am Soc Nephrol 2001;12 Suppl 17: S48-S52.
17. Mariat C, Alamartine E, Diab N, De Filippis JP, Laurent B, Berthoux F. A randomized prospective study comparing low-dose OKT3 to low-dose ATG for the treatment of acute steroid-resistant rejection episodes in kidney transplant recipients. Transpl Int 1998;11: 231-236.
18. Mestre M, Bas J, Alsina J, Grinyo JM, Buendia E. Depleting effect of antithymocyte globulin on T-lymphocyte subsets in kidney transplantation. Transplant Proc 1999;31: 2254-2255.
19. Bacigalupo A. Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effects. Bone Marrow Transplant 2005;35: 225-231.
20. Huurman VA, Kalpoe JS, van de LP et al. Choice of antibody immunotherapy influences cytomegalovirus viremia in simultaneous pancreas-kidney transplant recipients. Diabetes Care 2006;29: 842-847.
21. Meier-Kriesche HU, Arndorfer JA, Kaplan B. Association of antibody induction with short- and long-term cause-specific mortality in renal transplant recipients. J Am Soc Nephrol 2002;13: 769-772.
22. Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993;342: 1514-1516.
23. Bustami RT, Ojo AO, Wolfe RA et al. Immunosuppression and the risk of post- transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant 2004;4: 87-93.
24. Stratta RJ, Taylor RJ, Sindhi R, Sudan D, Castaldo P, Radio S. Is there a transfusion effect in combined pancreas-kidney transplantation? Transplant Proc 1995;27: 3096.
25. Claas FHJ, de Koster HS, Lagaaij EL, van Rood JJ. A molecular mechanism of T cell downregulation by blood transfusion. Exp Nephrol 1993;1: 134-138.
26. Waanders MM, Roelen DL, Brand A, Claas FH. The putative mechanism of the immunomodulating effect of HLA-DR shared allogeneic blood transfusions on the alloimmune response. Transfus Med Rev 2005;19: 281-287.
27. Roelen D, Brand A, Claas FH. Pretransplant blood transfusions revisited: a role for CD(4+) regulatory T cells? Transplantation 2004;77: S26-S28.
28. Weimer R, Staak A, Susal C et al. ATG induction therapy: long-term effects on Th1 but not on Th2 responses. Transpl Int 2005;18: 226-236.
29. Kreijveld E, Koenen HJ, Klasen IS, Hilbrands LB, Joosten I. Following anti-CD25 treatment, a functional CD4+CD25+ regulatory T-cell pool is present in renal transplant recipients. Am J Transplant 2007;7: 249-255.
30. Lopez M, Clarkson MR, Albin M, Sayegh MH, Najafian N. A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells. J Am Soc Nephrol 2006;17: 2844-2853.
31. Sanfilippo FP, Bollinger RR, MacQueen JM, Brooks BJ, Koepke JA. A randomized study comparing leukocyte-depleted versus packed red cell transfusions in prospective cadaver renal allograft recipients. Transfusion 1985;25: 116-119.